A Rare Case of Partial Peripheral Thyroid Hormone Resistance Due to a Point Mutation in the Membrane Integrin Α(V)Β(3) and Concomitant Hashimoto`s Thyroiditis.
Hashimoto’s thyroiditis
hypothyroidism
peripheral resistance
secondary hyperthyroidism
Journal
Open access Macedonian journal of medical sciences
ISSN: 1857-9655
Titre abrégé: Open Access Maced J Med Sci
Pays: North Macedonia
ID NLM: 101662294
Informations de publication
Date de publication:
30 Jun 2019
30 Jun 2019
Historique:
received:
27
05
2019
revised:
26
06
2019
accepted:
27
06
2019
entrez:
14
8
2019
pubmed:
14
8
2019
medline:
14
8
2019
Statut:
epublish
Résumé
Peripheral resistance to thyroid hormones is a type of unresponsiveness of the peripheral cells or tissues to FT3 and/or FT4. Generalised resistance to thyroid hormones affects the pituitary gland and most of the peripheral tissues. Selective pituitary resistance or central resistance to thyroid hormones include unresponsiveness of the pituitary gland, but the peripheral tissues are responsive. Selective peripheral resistance involves peripheral tissue or cellular resistance to thyroid hormones, but the pituitary gland is responsive. We present a rare case of a female patient with partial peripheral resistance to thyroid hormones due to a point mutation coding for the beta subunit of the integrin molecule α(V)β(3) and concomitant Hashimoto`s thyroiditis. Clinically, the patient`s symptoms were in favour of hypothyroidism, and the laboratory results were in favour of the secondary hyperthyroid state. PCR protein amplification detected a point mutation coding for the membrane receptor, which mediates a signal via the MAPK pathway when bonded with thyroid hormones. Peripheral resistance to thyroid hormones is a very rare condition and can often be misdiagnosed due to the broad spectrum of clinically similar differential diagnostic entities. Molecular analysis is required to confirm the exact underlying cause for the impaired peripheral sensitivity to thyroid hormones syndrome.
Sections du résumé
BACKGROUND
BACKGROUND
Peripheral resistance to thyroid hormones is a type of unresponsiveness of the peripheral cells or tissues to FT3 and/or FT4. Generalised resistance to thyroid hormones affects the pituitary gland and most of the peripheral tissues. Selective pituitary resistance or central resistance to thyroid hormones include unresponsiveness of the pituitary gland, but the peripheral tissues are responsive. Selective peripheral resistance involves peripheral tissue or cellular resistance to thyroid hormones, but the pituitary gland is responsive.
CASE PRESENTATION
METHODS
We present a rare case of a female patient with partial peripheral resistance to thyroid hormones due to a point mutation coding for the beta subunit of the integrin molecule α(V)β(3) and concomitant Hashimoto`s thyroiditis. Clinically, the patient`s symptoms were in favour of hypothyroidism, and the laboratory results were in favour of the secondary hyperthyroid state. PCR protein amplification detected a point mutation coding for the membrane receptor, which mediates a signal via the MAPK pathway when bonded with thyroid hormones.
CONCLUSION
CONCLUSIONS
Peripheral resistance to thyroid hormones is a very rare condition and can often be misdiagnosed due to the broad spectrum of clinically similar differential diagnostic entities. Molecular analysis is required to confirm the exact underlying cause for the impaired peripheral sensitivity to thyroid hormones syndrome.
Identifiants
pubmed: 31406543
doi: 10.3889/oamjms.2019.582
pii: OAMJMS-7-1991
pmc: PMC6684415
doi:
Types de publication
Case Reports
Langues
eng
Pagination
1991-1997Références
Genome Biol. 2007;8(5):215
pubmed: 17543136
Biochim Biophys Acta. 2013 Jul;1830(7):3987-4003
pubmed: 22986150
Thyroid. 2014 Mar;24(3):407-9
pubmed: 24588711
Best Pract Res Clin Endocrinol Metab. 2014 Mar;28(2):189-201
pubmed: 24629861
Physiol Rev. 2014 Apr;94(2):355-82
pubmed: 24692351
J Community Hosp Intern Med Perspect. 2014 Nov 25;4(5):25734
pubmed: 25432652
Arq Bras Endocrinol Metabol. 2014 Dec;58(9):962-6
pubmed: 25627054
J Clin Endocrinol Metab. 2015 Jul;100(7):2511-4
pubmed: 25867808
Proc (Bayl Univ Med Cent). 2016 Apr;29(2):209-11
pubmed: 27034574
Lancet. 2016 Aug 27;388(10047):906-918
pubmed: 27038492
Endocr J. 2017 Feb 27;64(2):207-212
pubmed: 27904073
J Endocrinol. 2018 Apr;237(1):R19-R34
pubmed: 29440347
Nat Rev Endocrinol. 2018 May;14(5):259-269
pubmed: 29472712
J Clin Endocrinol Metab. 2019 Jul 1;104(7):2473-2489
pubmed: 30020466
Curr Opin Endocrinol Diabetes Obes. 2018 Oct;25(5):341-346
pubmed: 30063552
Clin Case Rep. 2018 Jul 09;6(9):1684-1688
pubmed: 30214742
Int J Mol Sci. 2018 Oct 22;19(10):null
pubmed: 30360449
Oncotarget. 2018 Dec 11;9(97):37069-37075
pubmed: 30651936
Front Endocrinol (Lausanne). 2019 Feb 13;10:59
pubmed: 30814976
Am J Med. 1993 Apr;94(4):424-32
pubmed: 8475937
J Clin Invest. 1993 Jun;91(6):2408-15
pubmed: 8514853